AIM-HI Accelerator Fund

What AIM-HI Accelerator Fund does

AIM-HI Accelerator Fund is a 501(c)(3) nonprofit venture philanthropy organization founded in 2019 and headquartered in Rockville, Maryland. It was established with an initial capacity-building grant from the National Foundation for Cancer Research (NFCR) and operates as an oncology-focused seed-stage accelerator. The fund's core thesis is that early-stage oncology companies are systematically underfunded during the "Valley of Death" phase, when discoveries need to translate from lab to clinic and traditional VCs or pharma deem the risk too high. AIM-HI addresses this gap by providing catalytic pre-seed through Series A investment, mentorship, and strategic guidance to scientist-entrepreneur-led oncology startups globally.

AIM-HI's product surface consists of three annual venture competitions (AIM-HI Venture Competition, Women's Venture Competition, and the BRACE Award co-run with the Asian Fund for Cancer Research), a student fellowship program, the Beacon Award for Women Leaders in Oncology (est. 2022), and free legal seminars delivered in partnership with Cooley LLP. The fund does not build proprietary technology; rather, its "platform" is a curated ecosystem of scientific key opinion leaders, clinicians, experienced entrepreneurs, and co-investors (including QRAL Ventures) that evaluates and supports applicants. Since inception, AIM-HI has funded approximately 30 portfolio companies spanning molecular probes, CAR-T, antibody therapies, viral therapies, antibody-drug conjugates, diagnostics, and computational drug design (e.g., Rasio Therapeutics). A notable portfolio outcome is Tvardi Therapeutics, which merged with Cara Therapeutics in April 2025 to form a Nasdaq-listed entity (ticker: TVRD).

The business model is charitable donation- and grant-funded, not revenue-driven in the conventional sense. As a 501(c)(3), AIM-HI raises capital from individuals, donor-advised funds, gifts of stock, and grants, then deploys it as equity or convertible investment into portfolio companies, targeting sustainable returns to recycle into future cancer research. Its GTM relies on event-driven competition cycles, the co-branded NFCR Global Summit at the National Press Club, and media partnerships (e.g., OncoDaily). There is no pricing for services; portfolio companies receive capital and support in exchange for equity. NFCR (parent) provides backbone infrastructure, donor reach (5.7M donors, $420M cumulatively), and brand association, while AIM-HI maintains its own board and CEO.

Name

AIM-HI Accelerator Fund

Legal name

AIM-HI Accelerator Fund

Website

https://aim-hiaccelerator.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

AIM-HI Accelerator Fund is a 501(c)(3) nonprofit venture philanthropy organization that provides seed-stage investment, mentorship, and ecosystem support to early-stage oncology startups worldwide through competitive venture competitions, bridging the cancer research "Valley of Death" funding gap.

Ownership category

akta.pro rank

Product category

Venture Philanthropy / Impact Investing in Oncology

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Venture philanthropy fund
• Oncology seed investment
• Early-stage biotech accelerator
• Cancer research grants
• Nonprofit impact investing

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Charitable Donations and Grants: As a 501(c)(3) nonprofit organization, AIM-HI generates revenue through charitable donations from individuals and organizations. The fund was established in 2019 with an initial capacity-building grant from the National Foundation for Cancer Research (Tax ID: 82-4322538).
2. Venture Philanthropy Returns: The fund invests in early-stage oncology companies and generates sustainable revenues for future cancer research and social impact innovation. While they bridge the 'Valley of Death' funding gap, their returns are measured not only in fiscal return but in patient lives saved.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

AIM-HI Accelerator Fund is a 501(c)(3) nonprofit venture philanthropy organization that provides catalytic seed-stage equity investment, mentorship, and ecosystem support to early-stage oncology startups worldwide. Its core service is bridging the "Valley of Death" funding gap between laboratory cancer discoveries and clinical development through structured venture competitions (AIM-HI Venture Competition, Women's Venture Competition, BRACE Award) and reinvestment of returns into future cancer research.

Product overview

AIM-HI Accelerator Fund is a 501(c)(3) nonprofit organization established in 2019 as a venture philanthropy fund dedicated to advancing breakthrough cancer research from lab to clinic. The organization operates as an accelerator providing seed-stage investment and support to early-stage oncology startups through multiple interconnected programs: the AIM-HI Venture Competition (general oncology startups), Women's Venture Competition (women-led oncology companies), and BRACE Award Venture Competition (focused on underserved cancer populations). The fund supports portfolio companies developing cancer therapies and patient-empowering health technologies including molecular probes, immunotherapies, CAR-T technologies, antibody therapies, viral therapies, diagnostics, and drug delivery systems. Additional offerings include the annual NFCR Global Summit and Award Ceremonies, the Beacon Award for Women Leaders in Oncology, Student Fellowships, and free legal seminars provided through partnership with Cooley LLP. The organization has funded approximately 30 startup companies since inception.

Differentiator

Problem solved

Functional benefit

Brands

• AIM-HI Venture Competition: Annual venture competition providing catalytic early-stage investment, mentorship, strategic guidance, and visibility for oncology innovators from pre-seed through Series A.
• Women's Venture Competition
• BRACE Award Venture Competition
• Beacon Award for Women Leaders in Oncology

Products and services

• AIM-HI Venture Competition Annual competition that connects early-stage oncology founders with catalytic seed-stage equity investment, expert guidance from scientific and clinical leaders, and a global network of oncology innovation leaders to accelerate breakthrough science toward patient treatments. Open to pre-seed through Series A oncology companies worldwide.
• Women's Venture Competition First-of-its-kind program providing funding, coaching, and networking opportunities to women-led oncology startups with at least one woman in senior leadership holding an equity stake, addressing the documented underfunding of women ventures in biotech.
• BRACE Award Venture Competition Bridging Research from Academia to Cancer Entrepreneurship (BRACE) Award program supporting innovative early-stage oncology companies addressing cancers prevalent in underserved populations, co-hosted in partnership with the Asian Fund for Cancer Research.
• Student Fellowship Program providing opportunities for students interested in cancer research and oncology entrepreneurship to participate in AIM-HI's nonprofit accelerator ecosystem.
• NFCR Global Summit and Award Ceremonies Annual signature event co-hosted with the National Foundation for Cancer Research in Washington, D.C., bringing together world-renowned scientists, entrepreneurs, investors, and patient advocates to celebrate progress and chart new pathways in cancer research and entrepreneurship, including the AIM-HI Oncology Leadership and Entrepreneurship Forum.
• Beacon Award for Women Leaders in Oncology Established in 2022, this annual award recognizes outstanding women leaders in health and life sciences who have significantly impacted cancer treatment, detection, and diagnosis for patients worldwide; sponsored by the National Foundation for Cancer Research.
• Free Legal Seminars for Early-Stage Biotechs Complimentary virtual educational workshops provided by partner Cooley LLP covering corporate legal basics, IP protection, legal pitfalls, and university licensing transactions for early-stage biotech and life sciences companies.
• AIM-HI Accelerator Fund Investment Portfolio Catalytic seed-stage equity investments made into approximately 30 startup oncology and patient-empowering health-tech companies since 2019, including Akrotome Imaging, Arbele, Chimera Bio, DotBio, InterLeukin Combinatorial Therapies, InVaMet Therapeutics, ManaT Bio, Oncoheroes Biosciences, Privo Technologies, Rasio Therapeutics, SciTech Development, Sporos Bioventures, Stromatis Pharma, TellBio, Tvardi Therapeutics, Window Therapeutics, and Yiviva.

Quantifiable outcome

• Approximately 30 startup oncology and patient-empowering health-tech companies funded since inception
• +2 more outcomes

Named customers18 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• National Foundation for Cancer Research (NFCR)coreStrategic or Co-development Partner · 1 January 2019AIM-HI was established in 2019 with an initial capacity-building grant from NFCR. NFCR is the parent/co-founding organization - a 501(c)(3) nonprofit co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi. The two organizations co-host the annual NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship.
• Asian Fund for Cancer Research (AFCR)coreStrategic or Co-development Partner · 1 January 2019AFCR's BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award Venture Competition is co-hosted with AIM-HI to support and accelerate oncology innovations on their path toward commercialization. The partnership builds a unique program supporting innovative early-stage oncology companies addressing cancers prevalent in underserved populations.
• Cooley LLPcoreImplementation/ SI/ Consulting PartnerCooley LLP provides complimentary legal seminars for early-stage biotechs through AIM-HI. Sessions cover corporate legal basics, IP protection for startups, legal pitfalls to avoid, and life science university transactions/licensing. These workshops are provided via Zoom as part of AIM-HI's entrepreneur support ecosystem.
• MicrosoftminorGTM or Marketing PartnerMicrosoft is listed as a strategic partner on AIM-HI's website. Patty Obermaier, former Vice President of Microsoft Health, serves as Master of Ceremonies for AIM-HI forums and is on the Beacon Award Selection Committee.
• OncoDailyminorGTM or Marketing PartnerOncoDaily serves as media partner for the NFCR Global Summit events co-hosted by AIM-HI, providing media coverage and visibility for the organization and its activities.
• Dorsey & Whitney LLPminorImplementation/ SI/ Consulting PartnerPartner and Corporate Group Head Catherine Pan-Giordano delivered keynote address at AIM-HI Oncology Leadership and Entrepreneurship Forum highlighting importance of legal, organizational, and governance foundations for early-stage biotech ventures.
• Faegre Drinker Biddle & Reath LLPminorImplementation/ SI/ Consulting PartnerFaegre Drinker Biddle & Reath LLP is listed as a strategic partner of AIM-HI, providing legal and consulting support for the organization's activities and portfolio companies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• IndieBio: Biotech accelerator that funds and mentors early-stage science startups, including oncology-adjacent platforms. Comparable as a programmatic, competition-driven accelerator operating at the seed stage in therapeutics and biology.
• BioGenerator: St. Louis-based nonprofit biotech startup generator and investor that funds and incubates early-stage life-science companies. Highly comparable as a mission-driven, grant-and-venture-supported accelerator targeting biomedical founders in the seed/pre-seed gap.
• MBC BioLabs: Nonprofit biotech incubator providing fully equipped lab space and operational support to early-stage life-science startups. Comparable as a nonprofit infrastructure-and-support provider to seed-stage therapeutic companies, particularly in oncology-adjacent modalities.
• Damon Runyon Cancer Research Foundation: Nonprofit foundation funding high-impact cancer research and scientists, including early-career investigators whose work seeds future oncology startups. Comparable as a cancer-focused philanthropy that channels capital toward the oncology research-to-commercialization pipeline.
• Cancer Research Institute: Nonprofit organization dedicated to advancing immunology and immuno-oncology research funding and venture-style investments. Comparable as a cancer-focused nonprofit supporting both research and startup-creation in oncology.
• Asian Fund for Cancer Research: Nonprofit organization co-hosting the BRACE Award with AIM-HI to support early-stage oncology ventures addressing underserved populations. Directly comparable as a peer cancer-research nonprofit running venture-style competitions targeting translational oncology entrepreneurs.
• V Foundation for Cancer Research: Cancer research nonprofit founded by Jim Valvano that funds translational cancer research and supports early-stage oncology science. Comparable as a venture-philanthropy-style cancer nonprofit that backs researchers and translational programs.

Broad incumbents

• ARCH Venture Partners: Established venture capital firm investing in early-stage biotechnology companies, including oncology. Comparable as a deep-science, early-stage biotech investor but operates at much larger fund scale and with conventional return-driven structure.
• Alexandria LaunchLabs: Premium co-working and accelerator platform for early-stage life-science startups, part of Alexandria Real Estate Equities. Comparable as a venture-stage biotech incubator with ecosystem programming and capital connections, but operated by a publicly traded real-estate platform.
• JLABS by Johnson & Johnson: Global network of no-strings-attached biotech incubators operated by Johnson & Johnson for early-stage healthcare entrepreneurs. Comparable as a high-profile accelerator platform providing infrastructure, mentorship, and capital to early-stage life-science startups, but backed by a major pharma balance sheet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/intent/post?url=https%3A%2F%2Faim-hiaccelerator.org%2F&text=Home
• LinkedInlinkedin.com/shareArticle?mini=true&url=https%3A%2F%2Faim-hiaccelerator.org%2F&title=Home

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIM-HI Accelerator Fund